Business and Finance

The rise in product volume is more than matched by the rise of regulatory constraints

Looking at the essential value of well-managed supply chains

IMS Health/Ego Zender survey of CIOs finds short tenures and evolving skill sets

HDMA seeks to encourage more outreach to business partners and government

'Average Manufacturer Price' is now a mostly settled matter

Deal value soared above $300 billion in 2015, but will the dealmaking sustain Big Pharma companies?

Construction index shows a steady level of North American activity

'Innovation' is the recurring theme

HDMA's 2015-16 Factbook updates member financial, operational performance

European experience to date indicates a changing perspective on biosimilar pricing

Model N/Highpoint survey points to better integration of pricing and contract data

Company has 18 products in its US pipeline

Annual Beyond Borders report charts a boom that is continuing into 2015

Rebranding will affect 1,660 pharmacies and 80 clinics

Diana awards for Apotex, Eisai, Depomet and Bayer Healthcare in manufacturing

Olive Branch, MS; Shakopee, MN; and Newburgh, NY are the designated ABC sites

Novo Nordisk is tagged as the only 'high performer'

Effect of the first full year of Obamacare was muted, although a record number of prescriptions were written

Creation of a holding company streamlines future acquisitions; focus is on specialty drug services

More executional capabilities derive from affiliation with parent, inVentiv Health

$2-billion acquisition brings a $5-billion/yr PBM to Rite Aid's 4,600 retail stores

Association's annual specialty-distribution study focuses trend in oncology, chronic diseases

Reporting by pharma companies on spending on physicians is becoming a non-event

Analysis from Prime Therapeutics points to severe cost hurdles for biosimilars developed and marketed in the US